NCT03122041View on ClinicalTrials.gov

Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
PCOS
Interventions
DRUG

Sitagliptin

BEHAVIORAL

Lifestyle intervention

All Listed Sponsors
lead

University Medical Centre Ljubljana

OTHER

NCT03122041 - Sitagliptin Improved Beta Cell Function and Prevented a Conversion Rate to Impaired Glucose Tolerance and Type 2 Diabetes in Metformin Intolerant Obese Women With Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter